Private equity firm TPG Capital is eyeing about 10-times its money at clinical trials business Novotech.
It is understood the firm’s recent minority stake sale locked in a valuation at about 7½ times TPG’s initial investment, and recent momentum and equity market movements had it eyeing up to a stonking 10-times return should Novotech list in Hong Kong as planned.
That’s the sort of number that would make it TPG Capital’s best or second best investment in Asia, ever, limited partner sources told Street Talk. The other one occurred more than a decade ago, when it operated via its Newbridge Capital joint venture.
Goldman Sachs and UBS are lined up to float Novotech, as Street Talk revealed on Wednesday night. TPG’s expected to seek a $4 billion-plus valuation. Its recent Novotech selldown valued the company at $US2.3 billion ($2.95 billion).
Source: Financial Review
By Sarah Thompson, Anthony Macdonald and Tim Boyd
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.